Therapeutic Targeting of EP300/CBP by Bromodomain Inhibition in Hematologic Malignancies

In a subset of patients with relapsed or refractory disease, CCS1477 monotherapy induced differentiation responses in AML and objective responses in heavily pre-treated multiple myeloma.